e-learning
resources
2017
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Lung adenocarcinoma patients of young age have lower
EGFR
mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors
Shang-Gin Wu, Yih-Leong Chang, Chong-Jen Yu, Pan-Chyr Yang, Jin-Yuan Shih
Source:
ERJ Open Res, 3 (3) 00092-2016; 10.1183/23120541.00092-2016
Journal Issue:
July
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Shang-Gin Wu, Yih-Leong Chang, Chong-Jen Yu, Pan-Chyr Yang, Jin-Yuan Shih. Lung adenocarcinoma patients of young age have lower
EGFR
mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors. ERJ Open Res, 3 (3) 00092-2016; 10.1183/23120541.00092-2016
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
EGFR tyrosine kinase inhibitors
versus
chemotherapy in
EGFR
wild-type pre-treated advanced nonsmall cell lung cancer in daily practice
Source: Eur Respir J, 50 (2) 1700514; 10.1183/13993003.00514-2017
Year: 2017
Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma
Source: Eur Respir J 2012; 39: 366-372
Year: 2012
Uncommon EGFR mutations of lung adenocarcinoma in one tertiary institution, Korea: clinical characteristics and treatment response to tyrosine kinase inhibitors
Source: International Congress 2018 – Lung cancer: from the bench to the bedside
Year: 2018
Clinical profile of newly diagnosed patients of non small cell carcinima with epidermal growth factor receptor positivity on oral tyrosine kinase inhibitor therapy
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013
Better quality-of-life in patients with exon 19 deletion receiving first-line tyrosine kinase inhibitors for advanced non-small-cell lung cancer
Source: International Congress 2017 – Noteworthy lung cancer patient reports: reported outcome measures, smoking cessation, weight and sleep disorders
Year: 2017
Met amplification induces an aggressive phenotype in EGFR tyrosine kinase inhibitors resistant non-small-cell lung cancer
Source: International Congress 2015 – New frontiers in biomedical research on thoracic tumours
Year: 2015
The predictive value of circulating tumor DNA dynamics in plasma of EGFR-mutation-positive NSCLC patients on first line tyrosine kinase inhibitors
Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer
Year: 2021
Reduction of drug resistance through calcium control in epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) resistant lung cancer cells
Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer
Year: 2020
A temporal effect of EGFR tyrosine kinase inhibitor in lymphoepithelioma-like carcinoma of lung
Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology
Year: 2012
RON tyrosine kinase mutations in brain metastases from lung cancer
Source: ERJ Open Res, 4 (1) 00083-2017; 10.1183/23120541.00083-2017
Year: 2018
European mapping of EGFR mutation test and EGFR tyrosine kinase inhibitors availability in thoracic oncology
Source: International Congress 2015 – Quality management in lung cancer
Year: 2015
Outcomes of NSCLC patients with positive EGFR mutation
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up
Source: Eur Respir J 2009; 33: 436-440
Year: 2009
Epidermal growth factor receptor (EGFR) gene mutation testing prior to tyrosine kinase inhibitors (TKI) treatment – prospective data from the Czech TULUNG registry
Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology
Year: 2020
Comparison of NSCLC patient groups with activated EGFR mutations treated with three different tyrosine-kinase inhibitors (TKI): Real-life data from the Czech Republic
Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside
Year: 2017
Mutations of EGFR and k-ras genes and TK inhibitors. Are there differences between gefitinib and erlotinib?
Source: Annual Congress 2008 - Therapy of thoracic tumours
Year: 2008
Targeting STAT3 pathway signalling in EGFR TKI resistant NSCLC
Source: Virtual Congress 2020 – Chronic lung diseases: novel methods, diagnostics and biomarkers
Year: 2020
Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma
Source: Eur Respir J 2012; 39: 1551
Year: 2012
Nomogram to predict the presence of EGFR activating mutation in lung adenocarcinoma
Source: Eur Respir J 2012; 39: 1550-1551
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept